C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pathology, Research and Practice

• Publication date

  2013-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.prp.2013.02.002PMID 23490239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  2012cited by this paper
• Molecular targeted agents for gastric and gastroesophageal junction cancer

  2012cited by this paper
• Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

  2012cited by this paper
• Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

  2011cited by this paper
• MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

  2011cited by this paper
• Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa.

  2011cited by this paper
• MET and VEGF: synergistic targets in castration-resistant prostate cancer

  2011cited by this paper
• MET Expression and Amplification in Patients with Localized Gastric Cancer

  2011cited by this paper
• Expression of the c-Met Proteins in Malignant Skin Cancers.

  2011cited by this paper
• Kidney Cancer Pathology in the New Context of Targeted Therapy

  2011cited by this paper
• Head neck squamous cell carcinoma c‐Met+ cells display cancer stem cell properties and are responsible for cisplatin‐resistance and metastasis

  2011cited by this paper
• Development of c-MET pathway inhibitors

  2011cited by this paper
• Efficacy of c-Met inhibitor for advanced prostate cancer

  2010cited by this paper
• Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications

  2010cited by this paper
• MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions

  2010cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Comparison of Morphologic Features and Outcome of Resected Recurrent and Nonrecurrent Squamous Cell Carcinoma of the Penis: A Study of 81 Cases

  2009cited by this paper
• A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

  2008cited by this paper
• Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology.

  2008cited by this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

  2007cited by this paper
• Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  2007cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma

  2006cited by this paper
• Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.

  2005cited by this paper
• c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

  2003cited by this paper
• A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

  2003cited by this paper
• Tumor‐associated tissue eosinophilia of penile cancer

  2002cited by this paper
• Anatomic Levels: Important Landmarks in Penectomy Specimens: A Detailed Anatomic and Histologic Study Based on Examination of 44 Cases

  2001cited by this paper
• Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

  1997cited by this paper
• Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

  1995cited by this paper
• Expression and functional interaction of hepatocyte growth factor- scatter factor and its receptor c-met in mammalian brain

  1994cited by this paper
• Pathologic Features of Epidermoid Carcinoma of the Penis: A Prospective Study of 66 Cases

  1993cited by this paper
• Expression of the Met/HGF receptor in normal and neoplastic human tissues.

  1991cited by this paper
• Mechanism of met oncogene activation.

  1986cited by this paper
• Molecular cloning of a new transforming gene from a chemically transformed human cell line

  1984cited by this paper
• Clearing the hurdles ahead.

  1958cited by this paper
• SQUAMOUS‐CELL EPITHELIOMA OF THE SKIN A STUDY OF 256 CASES

  1921cited by this paper

• Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra‐operative detection and translational research

  2025cites this paper
• Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches

  2023cites this paper
• Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

  2022cites this paper
• c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients

  2021cites this paper
• Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies

  2021cites this paper
• Die molekulare Charakterisierung des Peniskarzinoms

  2018cites this paper
• Pathology, Molecular Biology, and Prognosis of Penile Squamous Cell Carcinoma: What Can We Learn from the Specimen?

  2018cites this paper
• A switch from epithelial to mesenchymal properties correlates with lymphovascular invasion in squamous cell carcinoma of the penis.

  2015cites this paper
• Novel targeted therapies for the treatment of penile cancer

  2014cites this paper
• MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

  2014cites this paper
• FHACT: the FISH-based HPV-associated cancer test that detects nonrandom gain at four genomic loci as biomarkers of disease progression

  2014cites this paper
• High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer

  2014cites this paper